Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Chronic myelogenous leukemia (CML)
Stage/Subtype:  accelerated phase
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 86 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KB004-01, NCI-2011-00883, NCT01211691
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 201112026, NCI-2014-01309, NCI-2011-02328, POL-4, NCT01413568
Dasatinib and Decitabine in Treating Patients with Accelerated or Blastic Phase Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0333, NCI-2012-00014, CA180357, NCT01498445
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PRI-724-201, NCI-2012-01153, NCT01606579
Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-180-384, NCI-2012-00773, 2011-204, NCT01643603
Conventional and Regulatory T Cells in Treating Patients With Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
Natural Killer Cells before and after Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Nilotinib and Binimetinib in Treating Patients with Refractory or Advanced Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0128, NCI-2015-00044, NCT02225574
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy using Sirolimus in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 1825.00, NCI-2010-00230, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: 45 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Start Over